← All trials
NCT06332430
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 28, 2024
- Primary completion
- May 30, 2025
- Completion date
- May 30, 2026
- First posted
- Mar 27, 2024
- Last posted
- Oct 31, 2024
- Enrollment
- 27
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Canwell Biotech LimitedLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.